8-KOther Events

QUEST DIAGNOSTICS INC 8-K Report, Corporate Update (Aug 18, 2021)

Filed August 18, 2021For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on August 18, 2021, to disclose the outcome of a stockholder-submitted proposal at their 2021 annual meeting. The proposal, which sought to allow stockholders to act by written consent on matters requiring a vote, received majority support, with 50.6% of the voting power in favor. This indicates a significant shareholder desire for increased direct involvement in corporate decision-making beyond annual meetings. In response to this vote, the Board of Directors has reviewed the implications of enabling non-unanimous written consent. Following this review and a recommendation from the Governance Committee, the Board has determined it is advisable to permit stockholders to act by written consent that is not unanimous. Consequently, the Company plans to propose amendments to its Certificate of Incorporation at the 2022 annual meeting to implement this change, signaling a move towards greater shareholder rights and responsiveness by the company.

Key Highlights

  • 150.6% of Quest Diagnostics stockholders voted in favor of a proposal to allow action by written consent.
  • 2The stockholder proposal aimed to enable action by written consent with the minimum necessary votes, not requiring unanimous consent.
  • 3The Board of Directors has considered the implications of non-unanimous written consent.
  • 4The Board has determined it is advisable to provide stockholders with the right to act by written consent that is not unanimous.
  • 5Quest Diagnostics plans to seek stockholder approval for amendments to its Certificate of Incorporation at the 2022 annual meeting to enable this right.
  • 6This decision reflects a responsiveness to shareholder sentiment for increased governance flexibility.

Frequently Asked Questions

Action by written consent allows stockholders to vote on corporate matters outside of a formal meeting, provided a certain threshold of approval is met. This filing indicates that Quest Diagnostics is moving towards allowing this action without requiring every single stockholder to agree (non-unanimous consent).

This is significant as it grants shareholders more direct power to influence company decisions between annual meetings. A majority vote in favor shows shareholders want more say, and the company's agreement to pursue this change suggests a commitment to enhancing corporate governance and shareholder rights.

The company plans to propose the necessary amendments to its Certificate of Incorporation at the 2022 annual meeting of stockholders for approval. If approved, the right to act by written consent would be implemented thereafter.

The filing specifies that the Board determined it is advisable to provide the right to act by written consent that is *not unanimous*. The specifics of which matters can be acted upon and the exact voting thresholds will be detailed in the proposed amendments to the Certificate of Incorporation to be presented in 2022.